What the guidelines actually say

Both The Menopause Society and the International Society for the Study of Women's Sexual Health have published formal clinical guidance on testosterone use specifically for hypoactive sexual desire disorder, HSDD, in postmenopausal women. Current evidence supports systemic transdermal testosterone, kept within the normal premenopausal physiological range, as a moderate-benefit treatment specifically for HSDD, distinct from testosterone use for any other purpose (Kingsberg and colleagues, 2024 review).

Who this is actually for

This is specifically indicated for postmenopausal women with low sexual desire that causes real personal distress, not simply a lower libido that a woman is not particularly bothered by. That distinction matters clinically: the guidelines are built around HSDD as a diagnosis, meaning the low desire itself is causing distress, not just a change you have noticed and are at peace with.

What monitoring actually looks like

This is not a start-and-forget treatment. Guidelines specifically recommend measuring serum testosterone before starting, and again after three months, to confirm levels stay within the normal physiological range rather than climbing into a range associated with side effects. If there is no improvement in sexual function within three to six months, guidelines recommend discontinuing rather than continuing indefinitely on the chance it might eventually work. This kind of structured monitoring is part of why this should be a supervised medical decision, not a self-directed one.

What ongoing research is still filling in

A large UK-funded trial, ESTEEM, began in 2024 specifically to evaluate testosterone's cost-effectiveness and its impact on broader menopause-related quality of life, not just sexual function, with results expected around 2028. This reflects that while the sexual-function evidence is solid, research into testosterone's other potential effects in menopause is still actively developing. A 2025 review specifically summarizing the evidence for systemic testosterone in postmenopausal HSDD confirmed it as the most evidence-backed hormonal option for low desire specifically, while noting the same open questions this ongoing research is working to close (Obstetrical & Gynecological Survey, 2025), which is a fair thing to know going into the conversation rather than assuming every question is already answered.

What to actually ask your doctor

  • Whether your low desire meets the threshold this evidence base is built around, meaning it causes you real distress, not just a change you have noticed.
  • What baseline testosterone testing looks like, and when you would be retested.
  • What the realistic timeline is for judging whether it is working, since guidelines point to three to six months, not immediate results.
  • Whether transdermal delivery specifically is available and appropriate for you, since that is the form the strongest evidence is built around.

My Perspective

Testosterone therapy for women still carries an odd stigma, partly because it gets culturally coded as a "male hormone" topic, which obscures the fact that women produce it too and that real, guideline-backed evidence exists for using it here. This is not an experimental or fringe treatment. It has formal society guidelines, specific monitoring protocols, and a defined patient population it is meant for.

A note from Marilyn: This is education, not medical advice. Whether testosterone therapy is appropriate for you is a decision for you and your healthcare provider, based on your full picture, not something to pursue without medical supervision and monitoring. I am a nutrition specialist, not your physician.

The fuller picture of hormone changes across the menopause transition is in Estrogen Left the Chat: Biohacking Menopause. And Receipts can help you track your symptoms before and during any treatment decision, which is useful information for that three-to-six-month conversation.

Frequently asked questions

Is testosterone therapy for women actually backed by real guidelines?

Yes. Both The Menopause Society and the International Society for the Study of Women's Sexual Health have published formal clinical guidance specifically supporting systemic transdermal testosterone for hypoactive sexual desire disorder in postmenopausal women.

Who is testosterone therapy actually meant for?

Specifically postmenopausal women with low sexual desire that causes real personal distress, meeting the clinical threshold for hypoactive sexual desire disorder, not simply any noticed decrease in libido that is not causing distress.

How is testosterone therapy monitored?

Guidelines recommend testing serum testosterone before starting and again after three months to confirm levels stay in the normal physiological range, with discontinuation recommended if there is no improvement in sexual function within three to six months.

Is the evidence for testosterone in menopause still developing?

The evidence for its effect on sexual function specifically is well established. A major UK trial (ESTEEM) launched in 2024 to study its broader effects on menopause-related quality of life, with results expected around 2028, so some questions beyond sexual function are still being actively researched.